5 mM peptide

IN THE CLAIMS

Please cancel claims 1, 3, 11 - 13 and 16 - 28.

Please replace the following amended claims with a clean copy of said claims. A marked-up version is appended hereto as Appendix II.

2.(Once amended) A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of a cellulase, lipase, endoglucosidase H, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase and a protease and said polypeptide of interest comprises a T-cell epitope,

wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that one or more amino acid residues of the T-cell epitope are altered and

wherein an allergenic immunogenic response produced by said variant in an individual is less than said allergenic immunogenic response produced by said polypeptide of interest.

5.(Once amended) The variant of claim 2, wherein said polypeptide of interest is not recognized by said individual as endogenous to said individual.

7.(Once amended) The variant of claim 2, wherein said T-cell epitope is altered with amino acid substitutions.

8.(Once amended) A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of a cellulase, lipase, endoglucosidase H, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase and a protease and said polypeptide of interest comprises a T-cell epitope,

wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that an allergenic immunogenic response produced by said variant in an individual is less than said allergenic immunogenic response produced by said polypeptide of interest, wherein said T-cell epitope is altered by having a terminal portion of said polypeptide of interest comprising said T-cell epitope replaced with a corresponding terminal portion of a homolog of

said polypeptide of interest wherein said homolog does not comprise a T-cell epitope identical to said replaced T-cell epitope.

14.(Twice amended) A cleaning composition, an animal feed composition, or a composition for treating a textile comprising the variant of claim 2.

Please add the following new claims

29. The variant of claim 2, wherein said polypeptide of interest is a cellulase.

30. The variant of claim 29, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO. 222 or SEQ ID NO: 223.

31. The variant of claim 2, wherein said polypeptide of interest is a lipase.

32. The variant of claim 31, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO: 225 or SEQ ID NO: 226.

33. The variant of claim 2, wherein said polypeptide of interest is an endoglucosidase H.

34. The variant of claim 33, wherein the T-cell epitope of the polypeptide of interest corresponds to the amino acid sequence disclosed in SEQ ID NO: 228.

35. A reduced allergenic variant of a protease of interest, wherein said protease of interest comprises a T-cell epitope and said protease of interest is altered by having a terminal portion of the protease comprising said T-cell epitope replaced with a corresponding terminal portion of a homolog of said protease of interest,

wherein said homolog does not comprise a T-cell epitope identical to the replaced T-cell epitope and wherein said variant produces a lessened allergenic response in an individual compared to the protease of interest.

36. The variant of claim 35, wherein the protease of interest is a subtilisin

37. The variant of claim 35, wherein the variant comprises the amino acid sequence of SEQ ID NO: 236.

38. A cleaning composition, an animal feed composition, a contact lens cleaning solution or a composition for treating a textile comprising the variant of claim 8.

39. A cosmetic care formulation for skin, hair or oral care comprising the variant of claim 2.

40. A cosmetic care formulation for skin, hair or oral care comprising the variant of claim 35.

41. A reduced allergenic variant of a polypeptide of interest, wherein said polypeptide of interest is selected from the group consisting of a cellulase, lipase, endoglucosidase H, carbohydrase, reductase, oxidase, isomerase, transferase, kinase, phosphatase and a protease and said polypeptide of interest comprises a T-cell epitope,

wherein said variant differs from said polypeptide of interest by having an altered T-cell epitope such that at least two amino acid residues of the T-cell epitope are altered, and

wherein an allergenic immunogenic response produced by said variant is less in an individual than the allergenic immunogenic response produced by said polypeptide of interest.